Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7129987 | 1.00 | HTR1A (0.68) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL7122344 | 0.90 | HTR1A (0.55) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL7132089 | 0.90 | HTR1A (0.55) | HTR1ASLC6A4DRD2HTR2A | |
| SCHEMBL7125110 | 0.82 | HTR1A (0.76) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL7129070 | 0.82 | HTR1A (0.76) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL7920755 | 0.81 | HTR1A (1.00) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL5843574 | 0.81 | HTR1A (0.75) | HTR1ASLC6A4DRD2 | |
| SCHEMBL7919029 | 0.80 | HTR1A (1.00) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL7911446 | 0.79 | HTR1A (1.00) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL7918390 | 0.78 | HTR1A (1.00) | HTR1ASLC6A4DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6667322-B2 | Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-12-23 | — | — | US | claimed |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | WYETH | 2003-05-29 | — | — | US | claimed |
| US-6667322-B2 | Useful for treatment of diseases such as obsessive compulsive disorder, panic attacks, anxiety, sexual dysfunction, eating disorders, obesity, addictive disorders | WYETH | 2003-12-23 | — | — | US | disclosed |
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | WYETH | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100579-A1 | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole | TPH1, HTR1D, HTR1A | HTR1A 3/4885SLC6A4 60/4885DRD2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.